Clinical trial · Observational
Lactate Imaging as a Tumour Biomarker
Investigation of Lactate Measured Using Magnetic Resonance Spectroscopy as a Biomarker of Tumour Response
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project is designed to investigate whether measurements of lactate in tumours, made using a magnetic resonance technique similar to MRI, is an effective non-invasive method to detect whether some new targeted drugs are having their desired effect. The study hypothesis is that by using magnetic resonance spectroscopy techniques, we will be able to observe changes in tumour lactate levels in vivo, in response to treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnetic Resonance Imaging (MRI) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Lymphoma
- description
- Lymphoma patients before and after receiving standard CHOP therapy
- interventionNames
- Device: Magnetic Resonance Imaging (MRI)
- label
- Metastatic Colorectal
- description
- Patients with metastatic colorectal cancer
- interventionNames
- Device: Magnetic Resonance Imaging (MRI)
- label
- Phase 1
- description
- Patients enrolled in Phase 1 clinical trials of new agents, whose mechanism of action is expected to lead to changes in lactate concentration
- interventionNames
- Device: Magnetic Resonance Imaging (MRI)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: Cohort 1:lymphoma patients * minimum lesion size of 2cm * not pretreated but scheduled to be treated with CHOP (Cyclophosphamide, Hydroxydaunomycin,Oncovin and Prednisolone) Cohort 2:Colorectal patients * metastatic disease of at least 2cm * not pretreated Cohort 3:Phase 1 Drug Development * minimum lesion size at least 2cm Cohort 4: Brain * primary brain tumours receiving radiotherapy and temozolomide * cerebral lymphoma receiving standard chemotherapy Exclusion Criteria: * MRI incompatible metal implants * Claustrophobia * Inability to tolerate a 40 minute MRI scan
References
Publications (0)
Data not yet available